2024-1-4 Executive Team Meeting Notes

Date

04 Jan 2024

Attendees

Committee Member	Present	Absent
Kuffel, Gina (NIH/NCI) [C]	X
Amy Leblanc	X
Otridge, John (NIH/NCI) [C]	X
Kim, Erika (NIH/NCI) [E]	X
Sommers, Connie (NIH/NCI) [E]	X
Debbie Knapp
Toby Hecht	X
Ralph Parchment	X

Goals

Discuss updates to ICDC and define emerging strategies and priorities

SharePoint Site

https://nih.sharepoint.com/sites/NCI-CBIIT-FNL-ICDC-ICDCLeadershipGroups

Outstanding Action Items

Debbie to work with Ralph to write invitation for Jaime Modiano
Gina to speak with Debbie to arrange a meeting with Gerry to discuss data submission (Toby, Debbie, Phil)
Revisit new steering committee members in September (loop Connie into this discussion)

Agenda

Item	Who	Talking Points
Discussion with FidoCure	Dr. Gerald Post, Chief Medical Officer at FidoCure Ben Toussant, Vice President of Operations at FidoCure	Goals of the ICDC Types of data that FidoCure has Potential collaborations Data submissions
New ICDC Subcommittee: Cross-Species Mapping Committee (CSMC) Purpose: Facilitation of human-canine comparative data analysis from the ICDC and other nodes in the CRDC using interoperability components such as Cancer Data Aggregator and aligning with data standards	All	ICDC Cross-Species Mapping Collaboration.docx 1-pager Does this effort need a new subcommittee? Nicky Mason and James Dattilo are interested Activities Build consensus data standards between human and canine data elements Mapping existing data elements in the ICDC to caDSR II to facilitate the findability of canine data related to human data through platforms such as the Cancer Data Aggregator. How can we leverage a potential collaboration with Data for the Commons Good (DCG) team? The DCG team is in the process of mapping data elements from the Pediatric Cancer Data Commons to caDSRII and is willing to work with us to share common data elements CDEs
New ICDC Subcommittee: Longitudinal Data Acquisition and Use Committee (LDAUC) Purpose: Formulate scientific questions and use cases that can be used to interrogate longitudinal datasets that would justify the ingestion of such data into the ICDC..	All	New ICDC Subcommitee 1-pager Should we sunset the Best Practices Subcommittee? Matthew Breen has offered to lead this subcommittee Should we send the questionnaire out to all Steering Committee members? https://forms.office.com/g/jqc0vRqXfx
DGAB Updates	Kuffel, Gina (NIH/NCI) [C]	Recently Released ICDC Studies in Active Submission COTC021 Approved by SAC on 6/30/23 "Evaluation of Orally Administered mTOR inhibitor Rapamycin in Dogs in the Adjuvant Setting with Osteosarcoma" Dr. Amy LeBlanc Status: AWS creds have been provided for file transfer UBC03 Approved by SAC on 8/13/22 "Transcriptomic analyses of early stage bladder cancer in Scottish Terriers detected through screening" Status: Metadata transfer is in progress
New ICDC Bioinformatics Tutorial Website	Kuffel, Gina (NIH/NCI) [C]	Enables users to follow tutorial and set up their own analysis using the ICDC & the CGC https://cbiit.github.io/icdc-bioinformatics/
ICDC Biospecimen Data	Kuffel, Gina (NIH/NCI) [C]	Collect biospecimen data so that we can build a page in the ICDC application ICDC Biospecimen Data
Upcoming Steering Committee Meeting	Ralph Parchment	January meeting: Ralph will send out the minutes for approval

Minutes (Not Verbatim)

Discussion with FidoCure

_______________________

Specific AI Question:

-Tumor, mutation, drug targets, inform outcomes correlation between

-Build dataset and R & D

-Improve outcomes for patients with diagnostics and therapy

-FidoCure is actually called OneHealth, dogs can be an unparalleled comparative model. We have the largest canine cancer dataset in the world, approaching 2 billion data points. Working on both sides of the leash.

Previous ICDC Use Cases from Steering Committee

1. Genomic correlates across platforms (DNA, RNA, protein).

2. Correlating multi-omics data with clinical annotation and phenotypes, particularly outcomes.

3. Comparative analyses of canine and human. Examples include:

1. Search for conserved mutations between canine and human tumors

2. Disease diagnosis (e.g. cancer type) and classification mapping between canines and humans

5. Gene expression changes and mutational profiles associated with therapeutic response and outcome

6. How do sporadic tumors in non-human mammals compare to sporadic human tumors?

7. Correlations and model building from radiomic and pathomic features extracted from medical and histopathologic images with outcomes and genomics, as is currently being widely done with human images

8. Develop biomarkers of response and resistance in humans by analyzing the responses and genomic signatures in dogs.

Action items

Toby to invite Greg from CCDI to the next Executive Team Meeting in January
Toby to look across the NCI directory to find person that has a combination of canine and pediatric oncology background

Content

Space Tools